Search Results
Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6178 pages
Showing 101 - 150Conversations Between Physicians and Older Patients About Physical Activity May Reduce Falls During Cancer Treatment
Communication between health-care providers and older patients with cancer regarding the significance of physical activity may help reduce the risk of falls during cancer therapy, according to new findings presented by Lu and Zheng at the 2024 ASCO Quality Care Symposium (Abstract 224). Background...
FDA Approves Selpercatinib for RET Fusion–Positive Medullary Thyroid Cancer
On September 27, 2024, the U.S. Food and Drug Administration granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require...
Community-Academic Partnership May Successfully Reduce Radon-Related Lung Cancer Risk in Native Population
A community and academic partnership may provide effective education about the risks of radon, testing for radon, mitigating radon in homes with high levels of the chemical, and reducing the risk of developing lung cancer among Native community members residing in Wisconsin, according to new...
Olanzapine May Reduce Chemotherapy-Induced Nausea and Improve Quality of Life Among Patients With Cancer
Researchers have found that olanzapine may be more effective in controlling severe nausea and improving the quality of life in patients with cancer who are undergoing treatment with chemotherapy, according to new findings presented by Peppone et al at the 2024 ASCO Quality Care Symposium (Abstract...
Quality-of-Life Outcomes: Whole-Breast Irradiation vs Accelerated Partial-Breast Irradiation Following Breast-Conserving Surgery
A study by Ganz et al assessed quality-of-life outcomes following whole- or partial-breast radiation in patients with breast cancer who underwent lumpectomy. The researchers published their findings in the Journal of the National Cancer Institute. Study Methods and Results In the NRG Oncology...
Neighborhood Environment May Be Linked to Prostate Cancer Risk in Men With West African Genetic Ancestry
West African genetic ancestry may be associated with an increased risk of prostate cancer among men residing in disadvantaged neighborhoods but not among those residing in more affluent neighborhoods, according to a recent study published by Pichardo et al in JAMA Network Open. The findings...
FDA Approves Osimertinib in Stage III NSCLC After Chemoradiotherapy
On September 25, the U.S. Food and Drug Administration approved osimertinib (Tagrisso) for adults with locally advanced, unresectable (stage III) non–small cell lung cancer (NSCLC) whose disease has not progressed during or after concurrent or sequential platinum-based chemoradiation therapy. These ...
Adjuvant Pembrolizumab Following Surgery May Improve Cancer-Free Survival in Patients With High-Risk Urothelial Carcinoma
Treatment with the immunotherapy agent pembrolizumab may nearly double the length that patients with high-risk, muscle-invasive urothelial carcinoma are cancer free following surgical removal of the bladder, according to a recent study published by Apolo et al in The New England Journal of...
Black Patients With Triple-Negative Breast Cancer May Be Less Likely to Receive Immunotherapy Compared With White Patients
Black patients with triple-negative breast cancer may receive immunotherapy at lower rates than White patients, according to new findings presented by Freeman et al at the 2024 American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic...
World Cancer Research Day 2024: Pioneering Innovations for Global Health Equity
World Cancer Day is marked every year on September 24 and seeks to raise awareness of the importance of cancer research as a key driver of advances in prevention and therapeutic strategies that increase survival and reduce the global cancer burden. This year, World Cancer Research Day focuses on...
Sexual Health Symptoms May Be Linked to Poor Adherence to Adjuvant Endocrine Therapy in Black Women With Breast Cancer
Symptoms related to sexual health may be associated with decreased adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer, according to new findings presented by Anderson et al at the 2024 American Association for Cancer Research (AACR) Conference on the Science of ...
ACA May Increase Access to Colorectal Cancer Care Among Underserved Groups
The Affordable Care Act (ACA) has increased guideline-concordant care for colorectal cancer among non-White patients, those from rural areas, and those from the most deprived neighborhoods in Pennsylvania, according to new findings presented by Kudaravalli et al at the 2024 American Association for ...
Isatuximab Plus VRd Approved by FDA for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
On September 20, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody isatuximab-irfc (Sarclisa) in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)....
Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma
Maeve Lowery, MD, discusses the results of the phase II DUBHE-H-308 trial, which evaluated QL1706—a bifunctional antibody consisting of iparomlimab and tuvonralimab—plus bevacizumab and/or chemotherapy in the first-line treatment of advanced hepatocellular carcinoma (Abstract LBA38).
Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib
Rachna T. Shroff, MD, MS, FASCO, was the discussant for a phase III trial presented at the ESMO Congress 2024 evaluating the efficacy and safety of anlotinib plus penpulimab vs sorafenib as first-line therapy for advanced hepatocellular carcinoma (Abstract LBA40).
Phase III CABINET Trial: Cabozantinib in Advanced Neuroendocrine Tumors
Cabozantinib may be effective at improving progression-free survival in patients with previously treated neuroendocrine tumors, according to recent findings presented by Chan et al at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract 1141O) and simultaneously published in The ...
Immunotherapy Combination May Improve Long-Term Survival in Patients With Metastatic Melanoma
Researchers have found that about 50% of patients with metastatic melanoma treated with a combination of nivolumab and ipilimumab experienced cancer-free survival of 10 years or longer, according to a recent study published by Wolchok et al in The New England Journal of Medicine. Background In...
FDA Approves Amivantamab-vmjw With Carboplatin and Pemetrexed for Non–Small Cell Lung Cancer With EGFR Exon 19 Deletions or L858R Mutations
On September 19, the U.S. Food and Drug Administration (FDA) approved amivantamab-vmjw (Rybrevant) with carboplatin and pemetrexed for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R...
Black Women May Have a Higher Risk of Mortality From all Breast Cancer Subtypes
Investigators have found that Black women may have a higher risk of dying from all subtypes of breast cancer compared with White women, according to a recent study published by Torres et al in the Journal of Clinical Oncology. The findings demonstrated that higher mortality rates among Black women...
Breast and Ovarian Cancers May Be Linked to Thousands of RAD51C Gene Variants
Researchers have identified thousands of genetic changes in a gene that may increase the risk of developing breast and ovarian cancers, according to a recent study published by Olvera-León et al in Cell. The findings may pave the way for better risk assessment and more personalized care. ...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 1
Medical oncology had a turbulent beginning. No other specialty we know of struggled as much. But by 1980, it had become a stable specialty of internal medicine and was off and running—with the major problem of how to marshal available resources to freely test the myriad opportunities presented by ...
FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
On September 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma. Efficacy and Safety Efficacy was investigated in KEYNOTE-483...
FDA Draft Guidance on Conducting Multiregional Oncology Clinical Trials
On September 16, the U.S. Food and Drug Administration (FDA) issued a draft guidance to provide sponsors with recommendations for conducting multiregional clinical trials in support of applications for drugs intended to treat cancer, according to a notice published in the Federal Register....
Novel Triplet Combination May Yield Positive Response in Patients With Advanced-Phase CML
Researchers have found that 80% of patients with previously treated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML)—including both accelerated or myeloid blast phases of the disease—or Philadelphia chromosome–positive acute myeloid leukemia (AML) may have achieved a bone marrow ...
Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma
Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further about how management of hepatocellular carcinoma differs across stages.
Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE
Josep M. Llovet, MD, PhD, presented the results of the phase III LEAP-012 trial, which evaluated the addition of lenvatinib plus pembrolizumab to transarterial chemoembolization (TACE), during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). For more insights into the...
Retifanlimab Plus Chemotherapy May Extend Progression-Free Survival in Patients With Squamous Cell Anal Carcinoma
Retifanlimab plus platinum-based chemotherapy may benefit patients with squamous cell anal carcinoma, according to new findings presented by Rao et al at a presidential symposium at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract LBA2). Background The incidence of squamous...
High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer
Results from the multicenter double-blind randomized phase III SOLARIS trial (Alliance A021703) showed that the addition of high-dose vitamin D3 to standard treatment did not improve progression-free survival vs standard-dose vitamin D3 in patients with untreated metastatic colorectal cancer. The...
Novel Antibody-Drug Conjugate Puxitatug Samrotecan May Demonstrate Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial
The novel antibody-drug conjugate puxitatug samrotecan may have a manageable safety profile consistent with similar antibody-drug conjugates and demonstrated initial efficacy in patients with heavily pretreated advanced or metastatic solid tumors, according to new findings presented by...
NIAGARA Trial: Perioperative Durvalumab Reduced Risk of Recurrence or Death vs Neoadjuvant Chemotherapy Alone in Muscle-Invasive Bladder Cancer
Positive results from the phase III NIAGARA trial showed perioperative treatment with the PD-L1 blocker durvalumab in combination with neoadjuvant chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key...
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma
In light of the landmark 5-year overall survival results from HIMALAYA, Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, discuss how to choose among the various doublet immunotherapy options for unresectable hepatocellular...
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Unresectable Hepatocellular Carcinoma: 5-Year Overall Survival Results From the HIMALAYA Trial
Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, of Humanitas Cancer Center, Milan, discuss the 5-year overall survival results from the phase III HIMALAYA trial evaluating tremelimumab plus durvalumab in unresectable hepatocellular ...
Immunotherapy and Novel Targeted Drug Appear Beneficial in Women With Early-Stage Gynecologic Disease
Studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 reveal new groups of women with early-stage cervical1 and endometrial cancers2 who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, and a first-in-human study found...
Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers
The results of numerous large international studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 showed that immunotherapy improves long-term overall survival in patients with a variety of cancer types, including advanced melanoma,1,2 triple-negative breast cancer,3...
Nasal and Paranasal Sinus Cancer: Neoadjuvant Chemotherapy and Organ Preservation
Researchers have found that chemotherapy prior to surgery may reduce the amount of normal tissue that needs to be removed in patients with advanced nasal and paranasal sinus squamous cell carcinoma, according to recent findings presented by Saba et al at the European Society for Medical Oncology...
Two Recent Studies Provide Evidence That Breastfeeding After Breast Cancer May Be Safe
Women who breastfeed after treatment for breast cancer—including those with germline BRCA-mutated disease—may not be at increased risk of cancer recurrence or new breast cancers, according to two recent international studies presented by Blondeaux et al (Abstract 1815O) and Peccatori et al...
LEAP-012: Pembrolizumab Plus Lenvatinib Added to TACE Improved Progression-Free Survival in HCC
According to results of the first interim analysis of the phase III LEAP-012 trial, the anti–PD-1 therapy pembrolizumab plus the tyrosine kinase inhibitor lenvatinib, in combination with transarterial chemoembolization (TACE), significantly improved progression-free survival compared with TACE...
FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection
The U.S. Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq), including non–small cell lung cancer (NSCLC), small cell lung cancer...
NeoCOAST-2 Trial: Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC
Researchers have demonstrated that the combination of durvalumab with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan may yield high pathologic complete response rates in patients with resectable non–small cell lung cancer (NSCLC), according to findings presented by Cascone et al...
Using TROP2 Expression to Predict Outcomes in Advanced NSCLC
Researchers have uncovered that TROP2 expression as measured by quantitative continuous scoring may be a predictor of clinical outcomes in patients with advanced or metastatic non–small cell lung cancer (NSCLC) treated with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan,...
Study Compares Lung Cancer Screening Triage Protocols
The PanCan nodule management protocol may be superior at triaging lung cancer screening participants compared with the LungRADSv1.1 approach, according to new findings presented by McWilliams et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung...
Perioperative Nivolumab May Improve Event-Free Survival Compared With Neoadjuvant Nivolumab Plus Chemotherapy Alone in Patients With Resectable NSCLC
Adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery may be effective at reducing the risk of disease recurrence or mortality in patients with resectable non–small cell lung cancer (NSCLC) compared with neoadjuvant nivolumab plus chemotherapy alone, according to new...
IASLC Global Survey on Biomarker Testing Reveals Progress and Persistent Barriers in Lung Cancer Biomarker Testing
Despite significant improvements in the perception of biomarker testing compared with a 2018 survey, substantial barriers to implementation may persist globally, according to new findings presented by Smeltzer et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World...
Pathway to Developing Predictive Biomarkers for Immune Checkpoint Inhibitors in NSCLC
Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors, according to new findings presented by Kulasinghe et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on...
Youth E-Cigarette Use May Have Declined to Lowest Level in a Decade
A fewer number of U.S. youths have reported current use of e-cigarettes in 2024 compared with 2023, according to new findings published by Park-Lee et al in the Morbidity and Mortality Weekly Report. Background E-cigarettes and nicotine pouches are two categories of tobacco products the U.S. Food...
High Proportion of U.S. Men Older Than 45 Years May Have Misconceptions About Prostate Cancer Screening as Rates of Late-Stage Diagnoses Continue to Rise
Investigators have uncovered misconceptions and gaps in awareness regarding prostate cancer and screening guidelines in light of Prostate Cancer Awareness Month in September, according to a recent survey conducted by The Harris Poll. Background In 2024, an estimated 299,010 men will be diagnosed...
Artificial Intelligence Method Transforms Gene Mutation Prediction in Lung Cancer
Research suggests an artificial intelligence (AI) tool called DeepGEM may provide an advancement in genomic testing that offers an accurate, cost-effective, and timely method for gene mutation prediction from histopathology slides. The research was presented at the International Association for the ...
FDA Approves Ready-to-Use Version of Bortezomib for Subcutaneous Administration
The U.S. Food and Drug Administration (FDA) has approved a new presentation of bortezomib (Boruzu) for ready-to-use subcutaneous or intravenous administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. Bortezomib, a...
How Accurate Is Staging in Early Pancreatic Cancer?
Staging may be inaccurate in up to 80% of patients with early pancreatic cancer, according to a recent study published by Perrotta et al in JAMA. The findings underscored the need for advancements in diagnostic technology and staging, which may help to improve early pancreatic cancer treatment and...
Omitting 5-FU Bolus May Reduce Side Effects in Patients With Gastrointestinal Cancers
Investigators have found that administering fluorouracil (5-FU) through continuous infusion and omitting the bolus component in patients undergoing commonly used treatment regimens targeting metastatic gastrointestinal cancers may improve tolerability without reducing treatment efficacy or...
